ClinicalTrials.gg
CompletedNCT02773368DUALTM IXUpdated Aug 11, 2020Results posted

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus

A Phase 3 interventional study of insulin degludec/liraglutide and insulin glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 88 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-11.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
31st of 70
420 · median 384
Started
2016
with 5 others
Phase 3
49 of 70
2 open now
Registered
49th of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 31st largest by enrollment, is one of 6 that started in 2016, is one of 49 in phase 3, and was the 49th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted globally. The aim of this trial is comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i (sodium-glucose cotransporter 2 inhibitors) in subjects with type 2 diabetes mellitus.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 420 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - Male or female, age at least 18 years at the time of signing - Subjects diagnosed (clinically) with type 2 diabetes mellitus - 7.0-11.0% [53-97 mmol/mol] (both inclusive) by central laboratory analysis - (BMI) equal to or above 20 kg/m\^2 and below 40 kg/m\^2 - Insulin naïve subjects; however short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as well as prior insulin treatment for gestational diabetes - A stable daily dose for at least 90 days prior to the day of screening of any SGLT2i in monotherapy or in combination with metformin ± DPP4i ± pioglitazone. Use of pioglitazone is not allowed in subjects treated with dapagliflozin Exclusion Criteria: - Receipt of any medicinal product within 90 days prior to screening - Use of any OADs (other than SGLT2i in monotherapy or in combination with metformin or DPP4i or pioglitazone as described in the inclusion criteria) within 90 days prior to the day of screening - Use of glucagon-like peptide-1 (GLP-1) receptor agonist (e.g., exenatide or liraglutide) within 90 days prior to the day of screening - Acute decompensation of glycaemic control requiring immediate intensification of treatment to prevent severe metabolic dysregulation (e.g., diabetes ketoacidosis) in the previous 90 days prior to the day of the screening - Subjects presently classified as being in (New York Heart Association) Class III or IV1 - Renal impairment estimated 60 mL/min/1.73 m2 as per CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) - Impaired liver function, defined as (alanine aminotransferase) equal to or above 2.5 times upper normal limit at screening - Known or suspected to trial product(s) or related products

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
420 participants (actual)

Study arms

  • Experimental
    IDegLira

    Drug: insulin degludec/liraglutide

  • Active comparator
    IGlar

    Drug: insulin glargine

Interventions

  • Druginsulin degludec/liraglutide

    Drug pages: Insulin degludec · Liraglutide

    IDegLira will be given subcutaneously ( s.c., under the skin) once daily.

  • IGlar will be given subcutaneously ( s.c., under the skin) once daily.

07

What researchers measure

Primary outcomes

  1. Change in HbA1c (Glycosylated Haemoglobin)

    The mean change from baseline (week 0) in HbA1c values evaluated after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.

    Time frame: Week 0, Week 26

Secondary outcomes

  1. Change in Body Weight

    The mean change from baseline (week 0) in body weight evaluated after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.

    Time frame: Week 0, Week 26

  2. Number of Treatment-emergent Severe or BG (Blood Glucose) Confirmed Symptomatic Hypoglycaemic Episodes

    Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe (subjects who were not able to self-treat) and/or BG confirmed by a plasma glucose values \<3.1 mmol/L (56 mg/dL) with accompanied symptoms consistent with hypoglycaemia.

    Time frame: Week 0-26

  3. Insulin Dose, Total Daily Dose (U)

    Actual daily total insulin dose (Units) was evaluated after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.

    Time frame: After 26 weeks

  4. Change in Fasting Plasma Glucose (FPG)

    Change from baseline (week 0) in FPG was evaluated after 26 weeks of randomised treatment.

    Time frame: Week 0, Week 26

  5. Number of Treatment-emergent Adverse Events

    Treatment emergent adverse events (TEAEs) were recorded from week 0 to week 26. TEAE was defined as an event that has onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.

    Time frame: Week 0-26

  6. Responder (Yes/No) for HbA1c Below 7.0%

    The proportion of subjects achieving pre-defined HbA1c targets \<7.0% after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.

    Time frame: After 26 weeks

  7. Responder After 26 Weeks (Yes/No) for: HbA1c < 7.0% Without Weight Gain

    The proportion of subjects achieving pre-defined HbA1c targets \<7.0% without weight gain after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.

    Time frame: After 26 weeks

  8. Responder After 26 Weeks (Yes/No) for: HbA1c < 7.0% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment

    The proportion of subjects achieving pre-defined HbA1c targets \<7.0% without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.

    Time frame: After 26 weeks

  9. Responder After 26 Weeks (Yes/No) for: HbA1c < 7.0% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment and Without Weight Gain

    The proportion of subjects achieving pre-defined HbA1c targets \<7.0% without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment and without weight gain. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.

    Time frame: After 26 weeks

  10. Responder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5%

    The proportion of subjects achieving pre-defined HbA1c targets ≤ 6.5% after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.

    Time frame: After 26 weeks

  11. Responder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5% Without Weight Gain

    The proportion of subjects achieving pre-defined HbA1c targets ≤ 6.5% without weight gain after 26 weeks of randomised treatment. The results are based on retrieved data at week 26 for subjects who prematurely discontinued the trial product.

    Time frame: After 26 weeks

  12. Responder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment

    The proportion of subjects achieving pre-defined HbA1c targets ≤ 6.5%without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.

    Time frame: After 26 weeks

  13. Responder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment and Without Weight Gain

    The proportion of subjects achieving pre-defined HbA1c targets ≤ 6.5%without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment and without weight gain. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.

    Time frame: After 26 weeks

  14. Change From Baseline After 26 Weeks in Waist Circumference

    Mean change from baseline in waist circumference after 26 weeks of randomised treatment.

    Time frame: After 26 weeks

  15. Change From Baseline in Fasting Lipid Profile: Cholesterol

    The values of total cholesterol from fasting lipid profile after 26 weeks of randomised treatment.

    Time frame: After 26 weeks

  16. Change From Baseline in Fasting Lipid Profile: Low-density Lipoprotein Cholesterol (LDL Cholesterol)

    The values of LDL cholesterol from fasting lipid profile after 26 weeks of randomised treatment.

    Time frame: After 26 weeks

  17. Change From Baseline in Fasting Lipid Profile: High-density Lipoprotein Cholesterol (HDL Cholesterol)

    The values of HDL cholesterol from fasting lipid profile after 26 weeks of randomised treatment.

    Time frame: After 26 weeks

  18. Change From Baseline in Fasting Lipid Profile: Very-low-density Lipoprotein Cholesterol (VLDL Cholesterol)

    The values of VLDL cholesterol from fasting lipid profile after 26 weeks of randomised treatment.

    Time frame: After 26 weeks

  19. Change From Baseline in Fasting Lipid Profile: Triglycerides

    The values of triglycerides from fasting lipid profile after 26 weeks of randomised treatment.

    Time frame: After 26 weeks

  20. Change From Baseline in Fasting Lipid Profile: Free Fatty Acids

    The values of free fatty acids from fasting lipid profile after 26 weeks of randomised treatment.

    Time frame: After 26 weeks

  21. Change From Baseline in the 9-point Self-measured Plasma Glucose (SMPG) Profile

    Change in 9-point SMPG profile was evaluated after 26 weeks of randomised treatment. SMPG measurements at baseline and week 26 are presented here at the following mentioned time points:1) Before breakfast, 2) 90 mins after the start of Breakfast, 3) Before lunch, 4) 90 mins after the start of lunch, 5) Before dinner, 6) 90 mins after the start of dinner, 7) At bedtime, 8) At 4 AM, 9) Before breakfast the following day.

    Time frame: After 26 weeks

  22. Change From Baseline in Self-measured Plasma Glucose (SMPG) 9-point Profile: Mean of the 9-point Profile

    Change in mean of the 9-point profile SMPG was evaluated after 26 weeks of randomised treatment. 9-point profile SMPG was measured at the following mentioned time points:1) Before breakfast, 2) 90 mins after the start of Breakfast, 3) Before lunch, 4) 90 mins after the start of lunch, 5) Before dinner, 6) 90 mins after the start of dinner, 7) At bedtime, 8) At 4 AM, 9) Before breakfast the following day.

    Time frame: After 26 weeks

  23. Change From Baseline in SMPG 9-point Profile: Prandial Plasma Glucose Increments (From Before Meal to 90 Min After Breakfast, Lunch and Dinner). The Mean Increment Over All Meals Will be Derived as the Mean of All Available Meal Increments

    Mean prandial plasma glucose increments for each meal (from before meal to 90 min after breakfast, lunch and dinner) was evaluated after 26 weeks of randomised treatment. The mean increment over all meals was derived as the mean of all available meal increments are presented here.

    Time frame: After 26 weeks

  24. Change From Baseline in Systolic Blood Pressure

    Change from baseline (week 0) in systolic blood pressure (BP) was evaluated after 26 weeks of randomised treatment.

    Time frame: After 26 weeks

  25. Change From Baseline in Diastolic Blood Pressure

    Change from baseline (week 0) in diastolic blood pressure was evaluated after 26 weeks of randomised treatment.

    Time frame: After 26 weeks

  26. Number of Treatment-emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During 26 Weeks

    Number of treatment-emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes (00:01-05:59 - inclusive) during 26 weeks of randomised treatment.

    Time frame: Week 0-26

  27. Number of Treatment-emergent Hypoglycaemic Episodes According to ADA Definition During 26 Weeks

    American Diabetes Association (ADA) classification of hypoglycaemic episodes: 1)Severe: Requiring assistance of another person to actively administer carbohydrate/glucagon/take other corrective actions. PG levels may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by a low PG level. 2) Documented symptomatic: PG ≤3.9 mmol/L with symptoms. 3) Asymptomatic: PG ≤3.9 mmol/L without symptoms. 4) Probable symptomatic: No measurement with symptoms. 5) Pseudo: PG \>3.9 mmol/L with symptoms. 6) Unclassifiable.

    Time frame: Week 0-26

  28. Change From Baseline in Clinical Evaluation After 26 Weeks: Electrocardiogram (ECG)

    Reported results are ECG findings at screening and week 26 of randomised treatment. Since the values measured at the baseline (week 0) were not collected, the screening data (week -2, which is \<= 2 weeks before baseline) is presented here. The findings are categorised as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). 4) Missing.

    Time frame: After 26 weeks

  29. Change From Baseline in Clinical Evaluation After 26 Weeks: Eye Examination: Fundoscopy/Fundus Photography

    Reported results are fundus photography/fundoscopy (for both left and right eye) findings at screening and week 26 of randomised treatment. Since the values measured at the baseline (week 0) were not collected, the screening data (week -2, which is \<= 2 weeks before baseline) is presented here. The findings are categorised as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). 4) Missing.

    Time frame: After 26 weeks

  30. Change From Baseline in Clinical Evaluation After 26 Weeks: Pulse Rate

    Change from baseline (week 0) in pulse rate was evaluated after 26 weeks of randomised treatment.

    Time frame: After 26 weeks

  31. Change From Baseline in Patient Reported Outcomes (PROs) After 26 Weeks: Summary Scores of Medical Outcomes Study 36-item Short Form (SF-36v2)

    The Short Form (SF)-36v2™ patient reported outcomes (PRO) questionnaire was used to assess the subject's overall health related quality of life (HRQoL). PRO questionnaire (SF-36v2™) measured the HRQoL which contains 36 items covering 8 domains of physical and mental health status. The raw scale scores from the SF-36 were transformed to a 0-100 scale scores (where higher scores indicated a better health status) which is further converted to norm-based scores using a T-score transformation in order to obtain a direct interpretation in relation to the distribution of the scores in the 2009 reference population . The total/overall (SF-36v2™) scores for physical and mental health from baseline to week 26 are presented here.

    Time frame: After 26 weeks

  32. Change From Baseline in Patient Reported Outcomes (PROs) After 26 Weeks: Summary Scores of Treatment Related Impact Measure for Diabetes (TRIM-D)

    The patient reported outcomes are calculated based on TRIM-D questionnaire. The TRIM-D questionnaire consists of 5 sub-domains (treatment burden, daily life, diabetes management, compliance and psychological health), where each question is scored to a 1-5-point scale with a higher score indicating a better health state (less negative impact). Mean TRIM-D domain scores and the total scores are later transformed to a 0-100 scale for analysis. Summary scores from baseline and week 26 for total/overall scores are presented here.

    Time frame: After 26 weeks

08

Results

Posted Oct 23, 2018

Participant flow

The trial was conducted at 74 sites in 11 countries as follows: Argentina (3), Canada (5), Finland (6), Hungary (5), India (8), Russian Federation (7), Slovakia (5), Slovenia (4), Spain (6), Switzerland (5) and United States (20).

Participant flow — Overall Study
MilestoneIDegLiraIGlar
Started210210
Exposed209210
Completed200206
Not completed104
Withdrew: Lost to follow-up41
Withdrew: Withdrawal by subject51
Withdrew: Unclassified11
Withdrew: Missing01

Outcome measures

PrimaryChange in HbA1c (Glycosylated Haemoglobin)

The mean change from baseline (week 0) in HbA1c values evaluated after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.

Time frame:
Week 0, Week 26
Reported as:
Mean · Percentage of glycosylated haemoglobin
Change in HbA1c (Glycosylated Haemoglobin)
Percentage of glycosylated haemoglobinIDegLiraIGlar
HbA1c (%) at baseline8.20 ± 0.938.36 ± 1.08
HbA1c (%) change from baseline to week 26-1.94 ± 0.95-1.68 ± 1.05
Statistical analysis
  • IDegLira vs IGlar · ANCOVA · Treatment contrast: -0.34 · 95% CI -0.48 to -0.20IDegLira minus IGlar
  • IDegLira vs IGlar · ANCOVA · Treatment contrast: -0.36 · 95% CI -0.50 to -0.21IDegLira minus IGlar
SecondaryChange in Body Weight

The mean change from baseline (week 0) in body weight evaluated after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.

Time frame:
Week 0, Week 26
Reported as:
Mean · kg
Change in Body Weight
kgIDegLiraIGlar
Body weight (kg) at baseline89.3 ± 17.687.2 ± 17.2
Body weight (kg) change from baseline to week 26-0.0 ± 3.82.0 ± 3.9
Statistical analysis
  • IDegLira vs IGlar · ANCOVA · Treatment contrast: -1.92 · 95% CI -2.64 to -1.19IDegLira minus IGlar
SecondaryNumber of Treatment-emergent Severe or BG (Blood Glucose) Confirmed Symptomatic Hypoglycaemic Episodes

Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe (subjects who were not able to self-treat) and/or BG confirmed by a plasma glucose values \<3.1 mmol/L (56 mg/dL) with accompanied symptoms consistent with hypoglycaemia.

Time frame:
Week 0-26
Reported as:
Number · Number of episodes
Number of Treatment-emergent Severe or BG (Blood Glucose) Confirmed Symptomatic Hypoglycaemic Episodes
Number of episodesIDegLiraIGlar
Number of Treatment-emergent Severe or BG (Blood Glucose) Confirmed Symptomatic Hypoglycaemic Episodes3895
Statistical analysis
  • IDegLira vs IGlar · Negative binomial regression model · Treatment ratio: 0.42 · 95% CI 0.23 to 0.75IDegLira over IGlar
SecondaryInsulin Dose, Total Daily Dose (U)

Actual daily total insulin dose (Units) was evaluated after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.

Time frame:
After 26 weeks
Reported as:
Mean · Units (U)
Insulin Dose, Total Daily Dose (U)
Units (U)IDegLiraIGlar
Insulin Dose, Total Daily Dose (U)36.2 ± 13.453.5 ± 26.1
Statistical analysis
  • IDegLira vs IGlar · ANCOVA · Treatment contrast: -15.37 · 95% CI -19.60 to -11.13IDegLira minus IGlar
SecondaryChange in Fasting Plasma Glucose (FPG)

Change from baseline (week 0) in FPG was evaluated after 26 weeks of randomised treatment.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/ L
Change in Fasting Plasma Glucose (FPG)
mmol/ LIDegLiraIGlar
FPG (mmol/L) at baseline9.51 ± 2.699.57 ± 2.40
FPG (mmol/L) change from baseline to week 26-3.72 ± 2.89-3.50 ± 2.43
SecondaryNumber of Treatment-emergent Adverse Events

Treatment emergent adverse events (TEAEs) were recorded from week 0 to week 26. TEAE was defined as an event that has onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.

Time frame:
Week 0-26
Reported as:
Number · Number of events
Number of Treatment-emergent Adverse Events
Number of eventsIDegLiraIGlar
Number of Treatment-emergent Adverse Events450386
SecondaryResponder (Yes/No) for HbA1c Below 7.0%

The proportion of subjects achieving pre-defined HbA1c targets \<7.0% after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.

Time frame:
After 26 weeks
Reported as:
Number · Participants
Responder (Yes/No) for HbA1c Below 7.0%
ParticipantsIDegLiraIGlar
Yes167144
No3058
SecondaryResponder After 26 Weeks (Yes/No) for: HbA1c < 7.0% Without Weight Gain

The proportion of subjects achieving pre-defined HbA1c targets \<7.0% without weight gain after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.

Time frame:
After 26 weeks
Reported as:
Number · Participants
Responder After 26 Weeks (Yes/No) for: HbA1c < 7.0% Without Weight Gain
ParticipantsIDegLiraIGlar
Yes9138
No106164
SecondaryResponder After 26 Weeks (Yes/No) for: HbA1c < 7.0% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment

The proportion of subjects achieving pre-defined HbA1c targets \<7.0% without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.

Time frame:
After 26 weeks
Reported as:
Number · Participants
Responder After 26 Weeks (Yes/No) for: HbA1c < 7.0% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment
ParticipantsIDegLiraIGlar
Yes156114
No4188
SecondaryResponder After 26 Weeks (Yes/No) for: HbA1c < 7.0% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment and Without Weight Gain

The proportion of subjects achieving pre-defined HbA1c targets \<7.0% without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment and without weight gain. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.

Time frame:
After 26 weeks
Reported as:
Number · Participants
Responder After 26 Weeks (Yes/No) for: HbA1c < 7.0% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment and Without Weight Gain
ParticipantsIDegLiraIGlar
Yes8334
No114168
SecondaryResponder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5%

The proportion of subjects achieving pre-defined HbA1c targets ≤ 6.5% after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.

Time frame:
After 26 weeks
Reported as:
Number · Participants
Responder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5%
ParticipantsIDegLiraIGlar
Yes147100
No50102
SecondaryResponder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5% Without Weight Gain

The proportion of subjects achieving pre-defined HbA1c targets ≤ 6.5% without weight gain after 26 weeks of randomised treatment. The results are based on retrieved data at week 26 for subjects who prematurely discontinued the trial product.

Time frame:
After 26 weeks
Reported as:
Number · Participants
Responder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5% Without Weight Gain
ParticipantsIDegLiraIGlar
Yes8426
No113176
SecondaryResponder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment

The proportion of subjects achieving pre-defined HbA1c targets ≤ 6.5%without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.

Time frame:
After 26 weeks
Reported as:
Number · Particpants
Responder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment
ParticpantsIDegLiraIGlar
Yes13779
No60123
SecondaryResponder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment and Without Weight Gain

The proportion of subjects achieving pre-defined HbA1c targets ≤ 6.5%without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment and without weight gain. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.

Time frame:
After 26 weeks
Reported as:
Number · Partcipants
Responder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment and Without Weight Gain
PartcipantsIDegLiraIGlar
Yes7724
No120178
SecondaryChange From Baseline After 26 Weeks in Waist Circumference

Mean change from baseline in waist circumference after 26 weeks of randomised treatment.

Time frame:
After 26 weeks
Reported as:
Mean · cm
Change From Baseline After 26 Weeks in Waist Circumference
cmIDegLiraIGlar
Waist circum. (cm) at baseline105.9 ± 12.7104.7 ± 11.3
Waist circum. (cm) change from baseline to week 26-0.6 ± 4.60.7 ± 3.9
SecondaryChange From Baseline in Fasting Lipid Profile: Cholesterol

The values of total cholesterol from fasting lipid profile after 26 weeks of randomised treatment.

Time frame:
After 26 weeks
Reported as:
Median · mmol/L
Change From Baseline in Fasting Lipid Profile: Cholesterol
mmol/LIDegLiraIGlar
Total cholesterol (mmol/L) at baseline4.42 (2.02 to 10.62)4.45 (2.12 to 11.37)
Total cholesterol (mmol/L) at week 264.27 (2.12 to 9.87)4.27 (1.84 to 9.40)
SecondaryChange From Baseline in Fasting Lipid Profile: Low-density Lipoprotein Cholesterol (LDL Cholesterol)

The values of LDL cholesterol from fasting lipid profile after 26 weeks of randomised treatment.

Time frame:
After 26 weeks
Reported as:
Median · mmol/L
Change From Baseline in Fasting Lipid Profile: Low-density Lipoprotein Cholesterol (LDL Cholesterol)
mmol/LIDegLiraIGlar
LDL cholesterol (mmol/L) at baseline2.28 (0.26 to 7.10)2.28 (0.10 to 6.73)
LDL cholesterol (mmol/L) at week 262.20 (0.57 to 6.42)2.31 (0.62 to 5.34)
SecondaryChange From Baseline in Fasting Lipid Profile: High-density Lipoprotein Cholesterol (HDL Cholesterol)

The values of HDL cholesterol from fasting lipid profile after 26 weeks of randomised treatment.

Time frame:
After 26 weeks
Reported as:
Median · mmol/L
Change From Baseline in Fasting Lipid Profile: High-density Lipoprotein Cholesterol (HDL Cholesterol)
mmol/LIDegLiraIGlar
HDL cholesterol (mmol/L) at baseline1.14 (0.57 to 2.69)1.14 (0.31 to 2.59)
HDL cholesterol (mmol/L) at week 261.17 (0.57 to 2.72)1.17 (0.36 to 2.49)
SecondaryChange From Baseline in Fasting Lipid Profile: Very-low-density Lipoprotein Cholesterol (VLDL Cholesterol)

The values of VLDL cholesterol from fasting lipid profile after 26 weeks of randomised treatment.

Time frame:
After 26 weeks
Reported as:
Median · mmol/L
Change From Baseline in Fasting Lipid Profile: Very-low-density Lipoprotein Cholesterol (VLDL Cholesterol)
mmol/LIDegLiraIGlar
VLDL cholesterol (mmol/L) at baseline0.75 (0.18 to 8.60)0.80 (0.21 to 8.13)
VLDL cholesterol (mmol/L) at week 260.70 (0.21 to 5.75)0.67 (0.21 to 3.32)
SecondaryChange From Baseline in Fasting Lipid Profile: Triglycerides

The values of triglycerides from fasting lipid profile after 26 weeks of randomised treatment.

Time frame:
After 26 weeks
Reported as:
Median · mmol/L
Change From Baseline in Fasting Lipid Profile: Triglycerides
mmol/LIDegLiraIGlar
Triglycerides (mmol/L) at baseline1.67 (0.38 to 23.60)1.73 (0.43 to 27.80)
Triglycerides (mmol/L) at week 261.55 (0.46 to 17.03)1.47 (0.47 to 8.81)
SecondaryChange From Baseline in Fasting Lipid Profile: Free Fatty Acids

The values of free fatty acids from fasting lipid profile after 26 weeks of randomised treatment.

Time frame:
After 26 weeks
Reported as:
Median · mmol/L
Change From Baseline in Fasting Lipid Profile: Free Fatty Acids
mmol/LIDegLiraIGlar
Free fatty acids (mmol/L) at baseline0.58 (0.08 to 1.44)0.61 (0.06 to 1.73)
Free fatty acids (mmol/L) at week 260.38 (0.10 to 0.92)0.42 (0.02 to 1.30)
SecondaryChange From Baseline in the 9-point Self-measured Plasma Glucose (SMPG) Profile

Change in 9-point SMPG profile was evaluated after 26 weeks of randomised treatment. SMPG measurements at baseline and week 26 are presented here at the following mentioned time points:1) Before breakfast, 2) 90 mins after the start of Breakfast, 3) Before lunch, 4) 90 mins after the start of lunch, 5) Before dinner, 6) 90 mins after the start of dinner, 7) At bedtime, 8) At 4 AM, 9) Before breakfast the following day.

Time frame:
After 26 weeks
Reported as:
Mean · mmol/L
Change From Baseline in the 9-point Self-measured Plasma Glucose (SMPG) Profile
mmol/LIDegLiraIGlar
Before breakfast - Baseline9.01 ± 2.189.00 ± 1.91
Ninety (90) minutes after breakfast - Baseline11.79 ± 3.0911.77 ± 2.99
Before lunch - Baseline8.93 ± 2.809.20 ± 2.95
Ninety (90) minutes after lunch - Baseline11.24 ± 3.2611.22 ± 3.06
Before dinner - Baseline9.33 ± 2.709.36 ± 2.89
Ninety (90) minutes after dinner - Baseline11.40 ± 3.0411.40 ± 2.99
At bedtime - Baseline10.38 ± 3.1610.71 ± 3.13
At 4.00 AM - Baseline8.80 ± 2.419.00 ± 2.50
Before breakfast the following day - Baseline8.60 ± 2.028.81 ± 1.92
Before breakfast - Week 265.40 ± 1.245.39 ± 1.21
Ninety (90) minutes after breakfast - Week 267.20 ± 1.868.35 ± 2.40
Before lunch - Week 265.83 ± 1.366.35 ± 1.88
Ninety (90) minutes after lunch - Week 267.25 ± 1.738.49 ± 2.28
Before dinner - Week 26:6.43 ± 1.616.77 ± 2.03
Ninety (90) minutes after dinner - Week 267.85 ± 1.958.70 ± 2.19
At bedtime - Week 267.05 ± 1.917.79 ± 2.20
At 4.00 AM - Week 265.58 ± 1.175.72 ± 1.51
Before breakfast the following day - Week 265.23 ± 1.095.36 ± 1.38
SecondaryChange From Baseline in Self-measured Plasma Glucose (SMPG) 9-point Profile: Mean of the 9-point Profile

Change in mean of the 9-point profile SMPG was evaluated after 26 weeks of randomised treatment. 9-point profile SMPG was measured at the following mentioned time points:1) Before breakfast, 2) 90 mins after the start of Breakfast, 3) Before lunch, 4) 90 mins after the start of lunch, 5) Before dinner, 6) 90 mins after the start of dinner, 7) At bedtime, 8) At 4 AM, 9) Before breakfast the following day.

Time frame:
After 26 weeks
Reported as:
Mean · mmol/L
Change From Baseline in Self-measured Plasma Glucose (SMPG) 9-point Profile: Mean of the 9-point Profile
mmol/LIDegLiraIGlar
Mean 9-point SMPG (mmol/L) at baseline9.98 ± 2.1710.06 ± 2.04
Mean 9-point SMPG change from baseline to week 26-3.47 ± 2.01-2.98 ± 1.91
SecondaryChange From Baseline in SMPG 9-point Profile: Prandial Plasma Glucose Increments (From Before Meal to 90 Min After Breakfast, Lunch and Dinner). The Mean Increment Over All Meals Will be Derived as the Mean of All Available Meal Increments

Mean prandial plasma glucose increments for each meal (from before meal to 90 min after breakfast, lunch and dinner) was evaluated after 26 weeks of randomised treatment. The mean increment over all meals was derived as the mean of all available meal increments are presented here.

Time frame:
After 26 weeks
Reported as:
Mean · mmol/L
Change From Baseline in SMPG 9-point Profile: Prandial Plasma Glucose Increments (From Before Meal to 90 Min After Breakfast, Lunch and Dinner). The Mean Increment Over All Meals Will be Derived as the Mean of All Available Meal Increments
mmol/LIDegLiraIGlar
Baseline2.38 ± 1.732.28 ± 1.88
Change from baseline to week 26-0.86 ± 1.95-0.09 ± 1.96
SecondaryChange From Baseline in Systolic Blood Pressure

Change from baseline (week 0) in systolic blood pressure (BP) was evaluated after 26 weeks of randomised treatment.

Time frame:
After 26 weeks
Reported as:
Mean · mmHg
Change From Baseline in Systolic Blood Pressure
mmHgIDegLiraIGlar
Systolic BP (mmHg) at baseline130.5 ± 14.3128.9 ± 13.1
Systolic BP (mmHg) change from baseline to week 26-3.0 ± 12.70.6 ± 12.0
SecondaryChange From Baseline in Diastolic Blood Pressure

Change from baseline (week 0) in diastolic blood pressure was evaluated after 26 weeks of randomised treatment.

Time frame:
After 26 weeks
Reported as:
Mean · mmHg
Change From Baseline in Diastolic Blood Pressure
mmHgIDegLiraIGlar
Diastolic (mmHg) at baseline79.4 ± 8.078.9 ± 8.9
Diastolic (mmHg) change from baseline to week 26-1.2 ± 8.4-1.1 ± 8.3
SecondaryNumber of Treatment-emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During 26 Weeks

Number of treatment-emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes (00:01-05:59 - inclusive) during 26 weeks of randomised treatment.

Time frame:
Week 0-26
Reported as:
Number · Number of episodes
Number of Treatment-emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During 26 Weeks
Number of episodesIDegLiraIGlar
Number of Treatment-emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During 26 Weeks613
SecondaryNumber of Treatment-emergent Hypoglycaemic Episodes According to ADA Definition During 26 Weeks

American Diabetes Association (ADA) classification of hypoglycaemic episodes: 1)Severe: Requiring assistance of another person to actively administer carbohydrate/glucagon/take other corrective actions. PG levels may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by a low PG level. 2) Documented symptomatic: PG ≤3.9 mmol/L with symptoms. 3) Asymptomatic: PG ≤3.9 mmol/L without symptoms. 4) Probable symptomatic: No measurement with symptoms. 5) Pseudo: PG \>3.9 mmol/L with symptoms. 6) Unclassifiable.

Time frame:
Week 0-26
Reported as:
Number · Number of episodes
Number of Treatment-emergent Hypoglycaemic Episodes According to ADA Definition During 26 Weeks
Number of episodesIDegLiraIGlar
Severe - ADA10
Documented symptomatic - ADA239419
Asymptomatic - ADA850902
Probably symptomatic - ADA235
Pseudo - ADA1014
Unclassifiable hypoglycaemia - ADA20
SecondaryChange From Baseline in Clinical Evaluation After 26 Weeks: Electrocardiogram (ECG)

Reported results are ECG findings at screening and week 26 of randomised treatment. Since the values measured at the baseline (week 0) were not collected, the screening data (week -2, which is \<= 2 weeks before baseline) is presented here. The findings are categorised as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). 4) Missing.

Time frame:
After 26 weeks
Reported as:
Number · Number of subjects
Change From Baseline in Clinical Evaluation After 26 Weeks: Electrocardiogram (ECG)
Number of subjectsIDegLiraIGlar
Screening, Normal142141
Screening, Abnormal NCS6669
Screening, Abnormal CS10
Screening, Missing00
Week 26, Normal134136
Week 26, Abnormal NCS5864
Week 26, Abnormal CS20
Week 26, Missing00
SecondaryChange From Baseline in Clinical Evaluation After 26 Weeks: Eye Examination: Fundoscopy/Fundus Photography

Reported results are fundus photography/fundoscopy (for both left and right eye) findings at screening and week 26 of randomised treatment. Since the values measured at the baseline (week 0) were not collected, the screening data (week -2, which is \<= 2 weeks before baseline) is presented here. The findings are categorised as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). 4) Missing.

Time frame:
After 26 weeks
Reported as:
Number · Number of subjects
Change From Baseline in Clinical Evaluation After 26 Weeks: Eye Examination: Fundoscopy/Fundus Photography
Number of subjectsIDegLiraIGlar
Screening, Left eye (Normal)134131
Screening, Left eye (Abnormal -NCS)6874
Screening, Left eye (Abnormal-CS)74
Screening, Left eye (Missing)00
Week 26, Left eye (Normal)123125
Week 26, Left eye (Abnormal -NCS)6668
Week 26, Left eye (Abnormal-CS)24
Week 26, Left eye (Missing)00
Screening, Right eye (Normal)133133
Screening, Right eye (Abnormal-NCS)6972
Screening, Right eye (Abnormal- CS)74
Screening, Right eye (Missing)00
Week 26, Right eye (Normal)120127
Week 26, Right eye (Abnormal-NCS)6966
Week 26, Right eye (Abnormal- CS)24
Week 26, Right eye (Missing)00
SecondaryChange From Baseline in Clinical Evaluation After 26 Weeks: Pulse Rate

Change from baseline (week 0) in pulse rate was evaluated after 26 weeks of randomised treatment.

Time frame:
After 26 weeks
Reported as:
Mean · Beats/minute
Change From Baseline in Clinical Evaluation After 26 Weeks: Pulse Rate
Beats/minuteIDegLiraIGlar
Pulse (beats/min) at baseline76.1 ± 9.175.0 ± 9.5
Pulse (beats/min) change from baseline to week 262.0 ± 8.4-0.4 ± 8.2
SecondaryChange From Baseline in Patient Reported Outcomes (PROs) After 26 Weeks: Summary Scores of Medical Outcomes Study 36-item Short Form (SF-36v2)

The Short Form (SF)-36v2™ patient reported outcomes (PRO) questionnaire was used to assess the subject's overall health related quality of life (HRQoL). PRO questionnaire (SF-36v2™) measured the HRQoL which contains 36 items covering 8 domains of physical and mental health status. The raw scale scores from the SF-36 were transformed to a 0-100 scale scores (where higher scores indicated a better health status) which is further converted to norm-based scores using a T-score transformation in order to obtain a direct interpretation in relation to the distribution of the scores in the 2009 reference population . The total/overall (SF-36v2™) scores for physical and mental health from baseline to week 26 are presented here.

Time frame:
After 26 weeks
Reported as:
Median · Scores on a scale
Change From Baseline in Patient Reported Outcomes (PROs) After 26 Weeks: Summary Scores of Medical Outcomes Study 36-item Short Form (SF-36v2)
Scores on a scaleIDegLiraIGlar
Overall physical - Baseline51.3 (22.0 to 61.6)51.5 (21.9 to 62.4)
Overall physical - Week 2653.2 (22.9 to 64.0)54.6 (25.0 to 65.6)
Overall mental - Baseline53.3 (15.6 to 67.9)53.3 (19.7 to 68.8)
Overall mental - Week 2654.4 (14.8 to 68.3)54.4 (31.0 to 67.3)
SecondaryChange From Baseline in Patient Reported Outcomes (PROs) After 26 Weeks: Summary Scores of Treatment Related Impact Measure for Diabetes (TRIM-D)

The patient reported outcomes are calculated based on TRIM-D questionnaire. The TRIM-D questionnaire consists of 5 sub-domains (treatment burden, daily life, diabetes management, compliance and psychological health), where each question is scored to a 1-5-point scale with a higher score indicating a better health state (less negative impact). Mean TRIM-D domain scores and the total scores are later transformed to a 0-100 scale for analysis. Summary scores from baseline and week 26 for total/overall scores are presented here.

Time frame:
After 26 weeks
Reported as:
Median · Scores on a scale
Change From Baseline in Patient Reported Outcomes (PROs) After 26 Weeks: Summary Scores of Treatment Related Impact Measure for Diabetes (TRIM-D)
Scores on a scaleIDegLiraIGlar
TRIM-D scores at baseline75.9 (44.6 to 100.0)75.9 (38.4 to 100.0)
TRIM-D scores at week 2684.4 (37.5 to 100.0)83.9 (44.6 to 100.0)

Adverse events

Collected over Adverse events (AEs) were collected from first day (week 0) of exposure to randomised treatment of 26 weeks + 30 days follow-up visits after the last dose on trial product. All reported AEs are treatment emergent (i.e., TEAE).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDegLira0/209 (0%)6/209 (2.9%)49/209 (23.4%)
IGlar0/210 (0%)7/210 (3.3%)45/210 (21.4%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventIDegLiraIGlar
PneumoniaInfections and infestations2/2091/210
Blood potassium increasedInvestigations1/2090/210
Cardiovascular evaluationInvestigations1/2090/210
Device failureProduct Issues1/2090/210
Haemorrhagic strokeNervous system disorders1/2090/210
Myocardial infarctionCardiac disorders1/2090/210
Abdominal painGastrointestinal disorders0/2091/210
Acute kidney injuryRenal and urinary disorders0/2091/210
Cardiac failure chronicCardiac disorders0/2091/210
Chronic kidney diseaseRenal and urinary disorders0/2091/210
Most frequent other events
Most frequent other events
EventIDegLiraIGlar
Viral upper respiratory tract infectionInfections and infestations16/20922/210
HeadacheNervous system disorders18/20919/210
Lipase increasedInvestigations12/2093/210
NauseaGastrointestinal disorders12/2091/210
Back painMusculoskeletal and connective tissue disorders11/2099/210

Baseline characteristics

The full analysis set (FAS) included all randomised subjects. The statistical evaluation of the FAS followed the intent-to-treat (ITT) principle and subjects contributed to the evaluation "as randomised".

Age, Continuous
Age, Continuous(years)IDegLiraIGlarTotal
Mean56.1 ± 10.457.2 ± 10.256.7 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)IDegLiraIGlarTotal
Female8984173
Male121126247
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IDegLiraIGlarTotal
Hispanic or Latino313768
Not Hispanic or Latino179173352
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IDegLiraIGlarTotal
American Indian or Alaska Native011
Asian313566
Native Hawaiian or Other Pacific Islander000
Black or African American325
White175171346
More than one race000
Unknown or Not Reported112
09

Study locations

88 sites
  • Novo Nordisk Investigational Site
    Glendale, Arizona 85308, United States
  • Novo Nordisk Investigational Site
    La Jolla, California 92037, United States
  • Novo Nordisk Investigational Site
    Mission Viejo, California 92691, United States
  • Novo Nordisk Investigational Site
    Northridge, California 91325, United States
  • Novo Nordisk Investigational Site
    Palm Springs, California 92262, United States
  • Novo Nordisk Investigational Site
    San Ramon, California 94583, United States
  • Novo Nordisk Investigational Site
    Boynton Beach, Florida 33472, United States
  • Novo Nordisk Investigational Site
    Chiefland, Florida 32626, United States
  • Novo Nordisk Investigational Site
    Skokie, Illinois 60077, United States
  • Novo Nordisk Investigational Site
    Avon, Indiana 46123, United States
  • Novo Nordisk Investigational Site
    Rockville, Maryland 20852, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89118, United States
  • Novo Nordisk Investigational Site
    Teaneck, New Jersey 07666, United States
  • Novo Nordisk Investigational Site
    Albany, New York 12206, United States
  • Novo Nordisk Investigational Site
    West Seneca, New York 14224, United States
  • Novo Nordisk Investigational Site
    Whiteville, North Carolina 28472, United States
  • Novo Nordisk Investigational Site
    Mason, Ohio 45040-6815, United States
  • Novo Nordisk Investigational Site
    Greer, South Carolina 29651, United States
  • Novo Nordisk Investigational Site
    Bristol, Tennessee 37620-7352, United States
  • Novo Nordisk Investigational Site
    Austin, Texas 78731, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77081, United States
  • Novo Nordisk Investigational Site
    Longview, Texas 75605, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78228-3419, United States
  • Novo Nordisk Investigational Site
    Kenosha, Wisconsin 53144, United States
  • Novo Nordisk Investigational Site
    Buenos Aires, C1425AGC, Argentina
  • Novo Nordisk Investigational Site
    Caba, C1120AAC, Argentina
  • Novo Nordisk Investigational Site
    Caba, C1180AAX, Argentina
  • Novo Nordisk Investigational Site
    Mendoza, 5500, Argentina
  • Novo Nordisk Investigational Site
    Winnipeg, Manitoba R2V 4W3, Canada
  • Novo Nordisk Investigational Site
    Moncton, New Brunswick E1G 1A7, Canada
  • Novo Nordisk Investigational Site
    Burlington, Ontario L7M 4Y1, Canada
  • Novo Nordisk Investigational Site
    London, Ontario N6G 2M1, Canada
  • Novo Nordisk Investigational Site
    Smiths Falls, Ontario K7A 4W8, Canada
  • Novo Nordisk Investigational Site
    Montreal, Quebec H4A 3T2, Canada
  • Novo Nordisk Investigational Site
    Helsinki, 00100, Finland
  • Novo Nordisk Investigational Site
    Lahti, 15110, Finland
  • Novo Nordisk Investigational Site
    Oulu, FI-90220, Finland
  • Novo Nordisk Investigational Site
    Rovaniemi, 96400, Finland
  • Novo Nordisk Investigational Site
    Tampere, 33520, Finland
  • Novo Nordisk Investigational Site
    Turku, 20520, Finland
  • Novo Nordisk Investigational Site
    Budapest, 1042, Hungary
  • Novo Nordisk Investigational Site
    Debrecen, 4043, Hungary
  • Novo Nordisk Investigational Site
    Komarom, 2900, Hungary
  • Novo Nordisk Investigational Site
    Salgótarján, 3100, Hungary
  • Novo Nordisk Investigational Site
    Szekszárd, 7100, Hungary
  • Novo Nordisk Investigational Site
    Zalaegerszeg, 8900, Hungary
  • Novo Nordisk Investigational Site
    Hyderbad, Andhra Pradesh 500 012, India
  • Novo Nordisk Investigational Site
    Bhopal, Madhya Pradesh 462037, India
  • Novo Nordisk Investigational Site
    Pune, Maharashtra 411040, India
  • Novo Nordisk Investigational Site
    Ludhiana, Punjab 141001, India
  • Novo Nordisk Investigational Site
    Jaipur, Rajasthan 302004, India
  • Novo Nordisk Investigational Site
    Chennai, Tamil Nadu 600029, India
  • Novo Nordisk Investigational Site
    Chennai, Tamil Nadu 600086, India
  • Novo Nordisk Investigational Site
    Varanasi, Uttar Pradesh 221105, India
  • Novo Nordisk Investigational Site
    Kolkata, West Bengal 700054, India
  • Novo Nordisk Investigational Site
    New Delhi, 110001, India
  • Novo Nordisk Investigational Site
    Barnaul, 656043, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 123423, Russian Federation
  • Novo Nordisk Investigational Site
    Novosibirsk, 630047, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 191119, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 194358, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petesburg, 195257, Russian Federation
  • Novo Nordisk Investigational Site
    St. Petersburg, 194354, Russian Federation
  • Novo Nordisk Investigational Site
    Kosice, 040 01, Slovakia
  • Novo Nordisk Investigational Site
    Lucenec, 984 01, Slovakia
  • Novo Nordisk Investigational Site
    Nitra, 94901, Slovakia
  • Novo Nordisk Investigational Site
    Presov, 080 01, Slovakia
  • Novo Nordisk Investigational Site
    Trnava, 91701, Slovakia
  • Novo Nordisk Investigational Site
    Celje, SI-3000, Slovenia
  • Novo Nordisk Investigational Site
    Koper, SI-6000, Slovenia
  • Novo Nordisk Investigational Site
    Kranj, 4000, Slovenia
  • Novo Nordisk Investigational Site
    Murska Sobota, SI-9000, Slovenia
  • Novo Nordisk Investigational Site
    Trbovlje, 1420, Slovenia
  • Novo Nordisk Investigational Site
    Almería, 04001, Spain
  • Novo Nordisk Investigational Site
    Antequera, 29200, Spain
  • Novo Nordisk Investigational Site
    Barcelona, 08035, Spain
  • Novo Nordisk Investigational Site
    Boadilla del Monte, 28660, Spain
  • Novo Nordisk Investigational Site
    Sevilla, 41003, Spain
  • Novo Nordisk Investigational Site
    Sevilla, 41009, Spain
  • Novo Nordisk Investigational Site
    Villamartin, 11650, Spain
  • Novo Nordisk Investigational Site
    Baden, 5400, Switzerland
  • Novo Nordisk Investigational Site
    Genève 14, 1211, Switzerland
  • Novo Nordisk Investigational Site
    Luzern 16, 6000, Switzerland
  • Novo Nordisk Investigational Site
    Olten, 4600, Switzerland
  • Novo Nordisk Investigational Site
    Schaffhausen, 8208, Switzerland
  • Novo Nordisk Investigational Site
    Winterthur, 8400, Switzerland
  • Novo Nordisk Investigational Site
    Zollikerberg, 8125, Switzerland
  • Novo Nordisk Investigational Site
    Zürich, 8091, Switzerland
10

References and documents

Publications

  • Philis-Tsimikas A, Billings LK, Busch R, Portillo CM, Sahay R, Halladin N, Eggert S, Begtrup K, Harris S. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2019 Jun;21(6):1399-1408. doi: 10.1111/dom.13666. Epub 2019 Apr 4. PubMed 30761720 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Sep 2017, 16 months.

Results were first posted in Oct 2018, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 16 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2016
First posted
May 16, 2016
StartActual
May 23, 2016
Primary completionActual
Sep 26, 2017
CompletionActual
Oct 23, 2017
Results first posted
Oct 23, 2018
Last update
Aug 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02773368
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 16, 2016
Start date
May 23, 2016
Primary completion
Sep 26, 2017
Completion
Oct 23, 2017
Results posted
Oct 23, 2018
Last update
Aug 11, 2020

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Liraglutide

Start the discussion